Episode 34: Why Nash Drug Trials Fail:A Thoughtful, Challenging Theory

Prof. Dr. Jörn M. Schattenberg joins the Surfers to discuss his recent article in Expert Opinion on Investigational Drugs dissecting recent drug trial failures.

Prof. Dr. Jörn M. Schattenberg g joins Stephen, Donna, Louise and Roger to discuss his recent article “The Nonalcoholic Steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successes.” The discussion started with lessons from failed trials, focusing on the importance of utilizing Phase 2 trials to test hypotheses and establish appropriate targets. From there, Surfers went on to discuss commercial and patient-focused definitions of what makes a clinical trial successful.

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"